Delivery Order SPE2DR25D3005-SPE2DR26FP8BD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 14, 2025, for the supply of Tolvaptan 15 mg tablets in unit-dose packaging of 10 units. This competitive award, valued at $44,199.07 on a firm fixed-price basis, is scheduled for completion by November 17, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Tolvaptan 15 mg tablets in unit dose packaging (10-count). The contract carries a ceiling value of $181,808 under a firm fixed-price arrangement with a completion date of July 15, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with the Defense Logistics Agency Troop...
- The Defense Logistics Agency awarded a delivery order valued at $21,076.03 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 30 mg tablets in unit-dose packaging of 10 units. This firm fixed-price delivery order, awarded on December 15, 2025, with an ultimate completion date of December 16, 2025, represents a competitive procurement with no set-aside designation. The pharmaceutical product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tolvaptan 15 mg tablets in unit dose packaging on September 9, 2025. This competitively awarded, non-set-aside contract is valued at $15,578.98 and requires completion by September 10, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, under a firm fixed-price arrangement typical of delivery orders against existing...
- The Defense Logistics Agency awarded a delivery order valued at $6,690.07 to AmerisourceBergen Drug Corp for Tolvaptan 15 mg tablets in unit dose packaging. This non-competitive delivery order, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a firm fixed price transaction for pharmaceutical supply. The contractor will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $15,233.64 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 15 mg tablets in unit dose packaging of 10s. This non-set-aside contract was competitively awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract utilizes firm fixed price pricing and represents a child delivery order issued under a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Tolvaptan 30 mg tablets in unit dose packaging of 10s. This contract is a non-set-aside, competitively awarded delivery order with firm fixed pricing, valued at $48,454.20, with a completion date of September 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, Corporate Office Division. The $4,930.47 fixed-price contract is for the supply of 4,565,379,180 units of Tolvaptan 30 mg tablets. The award has an ultimate completion date of August 8, 2024. AmerisourceBergen, a major pharmaceutical distributor, holds several Indefinite Delivery Contracts (IDCs) with federal agencies, including a $999,999,999 IDC with the DLA Troop Support Medical to...
- The Defense Logistics Agency awarded a delivery order valued at $38,125.72 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 30 mg tablets in unit dose packaging of 10 tablets per package. This is a firm fixed price, non-set-aside contract with a completion date of May 28, 2025. The award was issued on May 27, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tolvaptan is a vasopressin receptor antagonist used primarily...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Tolvaptan 15 mg tablets. The contract has a ceiling value of $5,077.88 and a completion date of May 28, 2025. It is not a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which...
- SPE2DR25D3005Indefinite Delivery Contract
- SPE2DR25D3005-SPE2DR26FP8BDDelivery Order
The Defense Logistics Agency awarded a $70,470.28 delivery order to AmerisourceBergen Drug Corp on December 15, 2025, for the supply of Tolvaptan 15 mg tablets in unit dose packages of 10. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award selection. Performance will be executed from the contractor's Conshohocken, Pennsylvania location, with an ultimate completion date of December 16, 2025. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor serving military and veteran healthcare systems through the DLA Medical Supply Chain. The company maintains an extensive portfolio of federal medical product deliveries encompassing prescription medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This Tolvaptan supply order supports the company's ongoing role as a primary pharmaceutical provider for Department of Defense medical operations, contributing to the broader mission of ensuring reliable pharmaceutical access across the military healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $70.5k | 12/14/25 |